key: cord-0749089-tgqprwwl authors: Fenemore, J. title: 191P Lung cancer care in Europe during COVID-19: Findings from a global survey of patient experience date: 2022-04-30 journal: Annals of Oncology DOI: 10.1016/j.annonc.2022.02.116 sha: 4e439c1945ad495a1f7a392003c9c7428ae7db8e doc_id: 749089 cord_uid: tgqprwwl nan Conclusions: Pts with thoracic malignancies achieve high proportion of seroconversion after two doses of mRNA-based vaccines, yet, anti-SARS-CoV-2 S1 IgG antibody levels decline substantially 3 and 6 months after the 2 nd vaccination, thus the 3 rd dose of vaccine is reasonable to provide adequate protection against severe COVID-19 disease course. Legal entity responsible for the study: The authors. Background: COVID-19 represents a large health care system consuming problem worldwide, and two years after its onset the real impact among non-COVID disease is still undetermined. Since the pandemic outbreak, cancer patients encountered profound changes in health care accessibility with an unknown impact in their diagnosis and treatment. We conducted a retrospective cohort study including a total of 500 first consult patients with lung cancer in a Portuguese Cancer Center during homologous time period, pre (2019) and in the COVID-19 era (2021). Our aim was to characterize and compare both groups in relation to patient's initial performance status, disease staging and patient's conditions to initiate systemic treatment, before and during COVID-19 pandemics. Conclusions: We believe that pandemic impact in non-COVID-19 patients, particularly in lung cancer population, is still an emerging and crescent problem that societies and health care systems will need to address in coming years as a concerted effort involving increased investment in the detection and treatment of cancer patients, in order to gradually recover pre-COVID-19 health levels. Legal entity responsible for the study: The authors. Methods: A multi-national steering group of patients, clinicians and advocates devised questions to explore: How easy patients found it to contact their medical team Whether patients had continued attending appointments in person Whether patients had experienced virtual consultations, and their view of them if so Questions were translated into multiple languages. GLCC members distributed the survey via emails and social media. Results were collated and analysed by the steering group. The GLCC produced a global report with findings for all participating countries, as well as bespoke reports for each country comparing national findings to the global picture. Results: Responses were received from 10 European nations: Bulgaria, Denmark, Greece, Ireland, Italy, Netherlands, Portugal, Spain, Sweden, and the UK. 494 of the 1,291 responding patients were from Europe (38%). Headline findings for Europe include: Many patients said there was no difference in how easy it was to contact their medical team. A proportion in almost all countries had found contact harder and some patients said they held back because their team was so busy Most patients had been able to see their medical team in person, but the majority in most countries also had telephone appointments. A smaller proportion of patients in only some countries had video calls The majority of patients in all countries prefer in person appointments, but many liked not having to travel to hospital. A small proportion found them difficult or said they wished to stop. Conclusions: Conclusion As healthcare systems recover from COVID-19, lung cancer patients' perspectives on virtual consultations must be considered to ensure they work for everyone, with alternatives and support available for those who find video or telephone difficult. All patients should be encouraged to contact their medical team when they need them, despite the pandemic. Legal entity responsible for the study: The author. Background: Radiation pneumonitis (RP) is the most common dose-limiting toxicity for thoracic radiation therapy. RP can cause substantial morbidity and often progresses to permanent fibrosis. Nintedanib is used for the treatment of idiopathic pulmonary fibrosis, which shares many pathophysiological pathways with the subacute phase of RP. Our goal was to investigate the efficacy and safety of nintedanib added to a standard prednisone taper compared to a prednisone taper alone in reducing pulmonary exacerbations in patients with grade 2 or higher (G2+) RP. Methods: In this phase II, randomized, double-blinded, placebo-controlled trial, patients with newly diagnosed G2+ RP were randomized 1:1 to nintedanib 150mg twice daily for 12 weeks or placebo, in addition to a standard 8-week prednisone taper. The primary endpoint was freedom from pulmonary exacerbations within one year. Secondary endpoints included total number of exacerbations and pulmonary function tests (PFTs). Kaplan-Meier analysis was used to estimate the probability of freedom from pulmonary exacerbation. The study was closed early due to slow accrual. Results: Thirty-four patients were enrolled, three patients withdrew consent, and one was not treated. Of the evaluable 30 patients, 18 were randomized to the experimental Arm A (nintedanib + prednisone taper) and 12 to control Arm B (placebo + prednisone taper). Freedom from exacerbation at one year was 72% (CI 54%-96%) in Arm A and 40% (CI 20%-82%) in Arm B (one-sided p¼0.037). In Arm A there were 16 G2+ adverse events possibly or probably related to treatment compared to five in the placebo arm. There were two deaths during the study period in arm A due to cardiac failure and progressive respiratory failure, respectively. No baseline patient characteristics were associated with freedom from exacerbations, and there were no statistically significant changes in PFTs between treatment arms. Conclusions: After the initial onset of G2+ RP, treatment with nintedanib plus prednisone taper improved freedom from pulmonary exacerbations at one year compared to placebo plus prednisone taper. These findings show promise for the use of nintedanib in the treatment of radiation pneumonitis. 193P Safety and efficacy of immmunotherapy rechallenge following a previous immune-induced interstitial lung disease Multidisciplinary Oncology and Therapeutic Innovation Dept ) months. The second episode of ICI-ILD appeared to be more severe than the first one, regarding both symptoms (38.5% vs 18.8 % of grade ! 3 ILD), and radiological features (higher number of lobes and intensity of CT-scan lesions after centralized review). One ICI-ILD related death was reported. 53.8% of patients recurred with a similar radiological pattern. Steroids use during rechallenge was not associated with ICI-ILD recurrence risk. Objective response rate and disease stabilization under ICI rechallenge were at 18.8% and 34.4%. Progression free survival and overall survival were not statistically Clinical trial identification: NCT02496585.Legal entity responsible for the study: The authors.